AZD-8055 - CAS 1009298-09-2
Catalog number:
Not Intended for Therapeutic Use. For research use only.
AZD-8055 is an inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/threonine kinase activity of mTOR, resulting in decreased expression of mRNAs necessary for cell cycle progression, which may induce cell cycle arrest and tumor cell apoptosis.
Publictions citing BOC Sciences Products
  • >> More
Light yellow to yellow solid
AZD8055; AZD 8055.
Current Developer:
1.C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.
Liu M1, Gu P1, Guo W2, Fan X3. Tumour Biol. 2016 Feb 20. [Epub ahead of print]
Aberrant activation of mammalian target of rapamycin (mTOR) plays pivotal roles in promoting hepatocellular carcinoma (HCC) tumorigenesis and chemoresistance. Here, we tested the potential anti-HCC activity by a novel mTOR complex 1/2 (mTORC1/2) dual inhibitor AZD-8055 and, more importantly, the potential AZD-8055 sensitization effect by a cell-permeable short-chain ceramide (C6). We showed that AZD-8055 mainly exerted moderate cytotoxic effect against a panel of HCC cell lines (HepG2, Hep3B, and SMMC-7721). Co-treatment of C6 ceramide remarkably augmented AZD-8055-induced HCC cytotoxicity. Meanwhile, C6 ceramide dramatically potentiated AZD-8055-induced HCC cell apoptotic death. Further studies demonstrated that AZD-8055 and C6 ceramide synergistically induced anti-survival and pro-apoptotic activity in primary cultured human HCC cells, but not in the non-cancerous human hepatocytes. Signaling studies showed that AZD-8055 and C6 ceramide synergistically suppressed Akt-mTOR complex 1/2 cascade activation.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mTOR Products

CAS 1223002-54-7 QL-IX-55

(CAS: 1223002-54-7)

The functional target of QL-IX-55 is the ATP-binding site of TOR2 as evidenced by the discovery of resistant alleles of TOR2 through rational design and unbiase...

CAS 958852-01-2 GSK1059615

(CAS: 958852-01-2)

GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively.

CAS 1207360-89-1 GDC-0349

(CAS: 1207360-89-1)

GDC-0349 is a small molecule anticaner drug candidate, being developed by Genentech. As of July 2012, Genentech has filed phase I trial of GDC-0349 for evaluati...

CAS 934493-76-2 Voxtalisib (XL-765)

Voxtalisib (XL-765)
(CAS: 934493-76-2)

SAR245409 (XL765) is a potent and highly selective pan inhibitor of class I PI3Ks (α/β/γ/δ, IC50=39/110/9/43 nM) with activity against mTOR(IC50=160-910 nM).

(CAS: 1382979-44-3)

GDC-0084, a PI3K inhibitor, has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. It was just li...

CAS 1086062-66-9 Omipalisib

(CAS: 1086062-66-9)

Omipalisib, also known as GSK2126458, is asmall-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic acti...

(CAS: 1685280-21-0)

DMH-25, a chromene derivative, could be a covalent mTOR inhibitor that has be found to exhibit activity in restraining the growth and metastasis of triple-negat...

CAS 6724-53-4 Perhexiline maleate salt

Perhexiline maleate salt
(CAS: 6724-53-4)

Perhexiline maleate salt is a carnitine palmitoyltransferase 1 (CPT1) and CPT2 inhibitor. It is an anti-anginal metabolic modulator and used in treatments for a...

(CAS: 1927857-61-1)

PQR530 is a potent dual pan PI3K/mTOR inhibitor undergoing phase II clinical trials in 2016. Aberrant activation of the PI3K/mTOR signaling pathway promotes the...

CAS 159351-69-6 Everolimus

(CAS: 159351-69-6)

Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) with an immunosuppressive activity which is comparable to that of rapamycin. It inhibits cyto...

CAS 1224844-38-5 MLN0128

(CAS: 1224844-38-5)

MLN0128, also known as INK128, is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR co...

(CAS: 1660110-65-5)

SC-III3 is a scopoletin derivative and has been found to induce the autophagy of hepatoma HepG2 cells so that could be significant in anticancer studies.

CAS 1429639-50-8 CZ415

(CAS: 1429639-50-8)

CZ415 is a highly selective potent mTOR inhibitor with little activity on other lipid and protein kinases with efficacy in a collagen induced arthritis model an...

CAS 1032754-81-6 GNE-477

(CAS: 1032754-81-6)

GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor with IC50 of 4 nM for PI3Kα and Kiapp of 21 nM for mTOR.

CAS 1032754-93-0 Apitolisib

(CAS: 1032754-93-0)

Apitolisib, also known as GDC-0980 and RG7422;  or GNE390, is a dual PI3 kinase/mTOR inhibitor,   is also an orally available agent targeting phosphatidylinosit...

(CAS: 1228013-30-6)

CC-223, a mTOR kinase inhibitor, has been found to be effective in inducing the apoptosis and reducing the proliferation of tumor cells. It is still under Phase...

CAS 1013101-36-4 PF-04691502

(CAS: 1013101-36-4)

PF-04691502 is a PI3K/mTOR kinase inhibitor, is also an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the...

CAS 1246535-95-4 Desmethyl-VS-5584

(CAS: 1246535-95-4)

Desmethyl-VS-5584, a demethyl analogue of VS-5584, is a PI3K/mTOR kinase inhibitor for the treatment of cancer.

CAS 1207358-59-5 mTOR-IN-1

(CAS: 1207358-59-5)

Selective inhibitors of mammalian target of rapamycin (mTOR) kinase based upon saturated heterocycles fused to a pyrimidine core were designed and synthesized. ...

CAS 53123-88-9 Rapamycin

(CAS: 53123-88-9)

Rapamycin is a mTOR inhibitor immunosuppressant and kinase inhibitor with both antifungal and antineoplastic properties. It selectively inhibits the transcripti...

Chemical Structure

CAS 1009298-09-2 AZD-8055

Quick Inquiry

Verification code

Featured Items